Korro Bio, Inc.

Class 005: Oligonucleotide preparations for the treatment of genetic diseases; Class 042: Pharmaceutical research and development in the fields of RNA editing, drug discovery and development

Custom manufacture of biomedical compounds comprised of nucleotide polymers and biomedical compounds comprised of ribonucleic acid polymers all for use in genetic research, pharmaceutical therapies, medical research and treatment of various conditions and disorders for others; Custom manufacture and processing of human cells for medical purposes for others; Treatment of therapeutic cells for others, namely, pharmacological treatment and processing of therapeutic cells to modify their function for therapeutic purposes; Pharmaceutical preparations for the treatment of genetic diseases; Pharmaceutical products for cell therapy to treat genetic diseases; Pharmaceutical research and development; Pharmaceutical research and development in the fields of gene therapies, gene editing, drug discovery and development; Pharmaceutical research and development incorporating artificial intelligence; Pharmaceutical research and development incorporating genetic learning; Scientific and industrial research; Scientific and industrial research incorporating artificial intelligence; Scientific and industrial research in the field of gene therapies, gene editing, drug discovery and development incorporating genetic learning; Medical and scientific research in the field of pharmaceuticals, genetics, gene editing, and genetic diseases

Custom manufacture of pharmaceuticals, namely, oligonucleotides and RNAs for use in genetic research, pharmaceutical therapies, medical research and treatment of various conditions and disorders; Oligonucleotide compounds being a component in pharmaceutical preparations for the treatment of genetic diseases and the repair and modulation of disease causing mutations and protein function; RNA compounds being a component in pharmaceutical preparations for the treatment of genetic diseases and the repair and modulation of disease causing mutations and protein function; RNA therapeutic agents for the treatment of genetic diseases and the repair and modulation of disease causing mutations and protein function; Nucleic acid therapeutic agents for the treatment of genetic diseases and the repair and modulation of disease causing mutations and protein function; Oligonucleotide compounds being a component in pharmaceutical preparations for use in RNA editing for treating genetic diseases; Oligonucleotide compounds being a component in pharmaceutical preparations for use in base editing for treating genetic diseases; Oligonucleotide compounds being a component in pharmaceutical preparations for use as RNA therapeutic for the treatment of genetic diseases and the repair and modulation of disease causing mutations and protein function; Oligonucleotide compounds being a component in pharmaceutical preparations for treating genetic diseases that facilitate the editing of RNA base; Pharmaceuticals, medicines, biologics, biotherapeutics, biosimilars and therapeutics, namely, nucleic acid therapeutic agents for the treatment of genetic diseases and the repair and modulation of disease causing mutations and protein function; pharmaceuticals, namely, bio-pharmaceutical preparations for the treatment of rare diseases

Custom manufacture of biomedical compounds comprised of nucleotide polymers and biomedical compounds comprised of ribonucleic acid polymers all for use in genetic research, pharmaceutical therapies, medical research and treatment of various conditions and disorders for others; Custom manufacture and processing of human cells for medical purposes for others; Treatment of therapeutic cells for others, namely, pharmacological treatment and processing of therapeutic cells to modify their function for therapeutic purposes; Oligonucleotide preparations for the treatment of genetic diseases; Pharmaceutical research and development; Pharmaceutical research and development in the fields of gene therapies, gene editing, drug discovery and development; Pharmaceutical research and development incorporating artificial intelligence; Pharmaceutical research and development incorporating genetic learning; Scientific and industrial research; Scientific and industrial research incorporating artificial intelligence; Scientific and industrial research in the field of gene therapies, gene editing, drug discovery and development incorporating genetic learning

Oligonucleotide preparations for the treatment of genetic diseases; Pharmaceutical research and development in the fields of gene therapies, gene editing, drug discovery and development

Custom manufacture of biomedical compounds comprised of nucleotide polymers and biomedical compounds comprised of ribonucleic acid polymers all for use in genetic research, pharmaceutical therapies, medical research and treatment of various conditions and disorders for others; Custom manufacture and processing of human cells for medical purposes for others; Treatment of therapeutic cells for others, namely, pharmacological treatment and processing of therapeutic cells to modify their function for therapeutic purposes; Pharmaceutical preparations for the treatment of genetic diseases; Pharmaceutical products for cell therapy to treat genetic diseases; Medical and scientific research in the field of pharmaceuticals, genetics, gene editing, and genetic diseases; Pharmaceutical research and development; Pharmaceutical research and development in the fields of gene therapies, gene editing, drug discovery and development; Pharmaceutical research and development incorporating artificial intelligence; Pharmaceutical research and development incorporating genetic learning; Scientific and industrial research; Scientific and industrial research incorporating artificial intelligence; Scientific and industrial research in the field of gene therapies, gene editing, drug discovery and development incorporating genetic learning; Medical and scientific research in the field of pharmaceuticals, genetics, gene editing, and genetic diseases

Pharmaceutical preparations for the treatment of rare genetic diseases; Pharmaceutical preparations containing biomedical compounds comprised of nucleotide polymers for the treatment of genetic diseases and the repair and modulation of disease causing mutations and protein function; Pharmaceutical preparations containing biomedical compounds comprised of ribonucleic acid polymers for the treatment of genetic diseases and the repair and modulation of disease causing mutations and protein function; RNA therapeutics for the treatment of genetic diseases and the repair and modulation of disease causing mutations and protein function; Nucleic acid therapeutics for the treatment of genetic diseases and the repair and modulation of disease causing mutations and protein function; Pharmaceutical preparations containing biomedical compounds comprised of nucleotide polymers for use in RNA editing; Pharmaceutical preparations containing biomedical compounds comprised of nucleotide polymers for use in base editing; Pharmaceutical preparations containing biomedical compounds comprised of nucleotide polymers for use as RNA therapeutic for the treatment of genetic diseases and the repair and modulation of disease causing mutations and protein function; Pharmaceuticals, medicines, biologics, biotherapeutics, biosimilars and therapeutics, namely, nucleic acid therapeutics for the treatment of genetic diseases and the repair and modulation of disease causing mutations and protein function; Pharmaceuticals, namely, bio-pharmaceutical preparations for the treatment of rare diseases; "BIO"

"BIO"; Pharmaceutical research and development; Pharmaceutical research and development in the fields of gene therapies, gene editing, drug discovery and development; Research and development of pharmaceutical products; Research and development in the field of bioscience; Research and development of biomedical compounds comprised of nucleotide polymers for use in targeted pharmaceutical therapies for the treatment of various conditions, diseases and disorders, including rare diseases, genetic disorders, liver diseases, eye diseases, and CNS disorders; Research and development of pharmaceutical preparations for the treatment of liver-based disorders, eye disorders and CNS disorders; Research and development of biomedical compounds comprised of nucleotide polymers for targeted RNA editing; Research and development of oligonucleotide drug platforms for use in the treatment of various conditions, diseases and disorders, including rare diseases, genetic disorders, liver diseases, eye diseases, and CNS disorders

Custom manufacture of biomedical compounds comprised of nucleotide polymers or biomedical compounds comprised of ribonucleic acid polymers for use in genetic research, pharmaceutical therapies, medical research and treatment of various conditions and disorders; "BIO"

Research and development of pharmaceutical products; research and development in the field of bioscience; research and development of oligonucleotide compounds for use in targeted pharmaceutical therapies for the treatment of various conditions, diseases and disorders, including rare diseases, genetic disorders, liver diseases, eye diseases, and CNS disorders; research and development of pharmaceutical preparations for the treatment of liver-based disorders, eye disorders and CNS disorders; research and development of oligonucleotide compounds for targeted RNA editing; research and development of oligonucleotide drug platforms for use in the treatment of various conditions, diseases and disorders, including rare diseases, genetic disorders, liver diseases, eye diseases, and CNS disorders

"BIO"